Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kymera Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for KT-333 to treat Relapsed/Refractory (R/R) Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL).
KT-333 is intended for the treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma. Credit: Nephron/commons.wikimedia.org.
Subscribe to our email newsletter
KT-333 is a highly selective degrader of STAT3, a transcriptional regulator that is linked to inflammatory and autoimmune diseases as well as various cancers.
The company is also developing KT-333 to treat several STAT3-dependent pathologies including haematological malignancies and solid tumours.
Last year, KT-333 received orphan drug designation from the FDA for the treatment of both CTCL and PTCL.
Kymera Therapeutics chief medical officer Jared Gollob said: “The KT-333 fast track designation highlights the promise of degrading STAT3, a protein that has historically been undruggable, for the treatment of patients with CTCL and PTCL.
“We look forward to providing an update on the KT-333 Phase I clinical trial later this year, including initial evaluation of its antitumour activity in the target patient populations, and to working with the lymphoma community to rapidly advance this first-in-class heterobifunctional degrader in CTCL and PTCL in addition to exploring its potential in other cancers.”
A Phase I study is evaluating the pharmacokinetics, pharmacodynamics, tolerability, and safety of KT-333 in adults with R/R leukemias, solid tumours and lymphomas.
Adult patients in this ongoing oncology trial will receive weekly doses of KT-333.
The fast track process will expedite new medicines access to patients more quickly.
